Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy

Cats, E.A., van der Pol, W.-L., Piepers, S., Franssen, H., Jacobs, B.C., van den Berg-Vos, R.M., Kuks, J.B., van Doorn, P.A., van Engelen, B.G., Verschuuren, J.J., Wokke, J.H., Veldink, J.H., van den Berg, L.H. · 2010 · Neurology

Abstract

OBJECTIVE: Identification and examination of all patients with multifocal motor neuropathy (MMN) in the Netherlands to document the clinical spectrum and response to IV immunoglobulin (IVIg) and to determine correlates of outcome. METHODS: A national cross-sectional descriptive study was performed. Ninety-seven patients were identified; 88 participated. Logistic regression analysis was used to study determinants of outcome. RESULTS: Age at onset was younger in men than in women (38 vs 45 years, p = 0.05). Onset of weakness was in distal arm (61%) or distal leg (34%), and occasionally in the upper arm (5%). Initial diagnosis was motor neuron disease in one-third of patients. Brisk, but not pathologic, reflexes in weakened muscles were found in 8%. Conduction blocks were most frequently detected in the ulnar (80%) and median (77%) nerves, but occasionally only between Erb and axilla (6%), or in the musculocutaneous nerve (1%). Ninety-four percent responded to IVIg therapy: nonresponders had longer disease duration before the first treatment (p = 0.03). Seventy-six percent received IVIg maintenance treatment at the time of this study (median duration 6 years; range 0-17): the median dose increased over the years from 12 to 17 g per week (p < 0.01). Independent determinants of more severe weakness and disability were axon loss (p < 0.001; p < 0.0001) and longer disease duration without IVIg (p = 0.03; p = 0.07). CONCLUSION: The results of this study may help aid recognition the clinical picture of MMN. Early IVIg treatment may help to postpone axonal degeneration and permanent deficits. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that IVIg improves muscle strength of patients with MMN and disability (defined as an increase of >or=1 Medical Research Council grade in at least 2 muscle groups without decrease in other muscle groups) in 94% (95% confidence interval, 86.8%-97.4%) of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181f0738e

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 194

Metadata

Authors
Cats, E. A., van der Pol, W.-L., Piepers, S., Franssen, H., Jacobs, B. C., van den Berg-Vos, R. M., Kuks, J. B., van Doorn, P. A., van Engelen, B. G., Verschuuren, J. J., Wokke, J. H., Veldink, J. H., & van den Berg, L. H.
Venue
Neurology
Published
2010-08-31
Volume
75
Issue
9
Pages
818-825
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2030866699
Cited by
194
References
1
FWCI
9.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181f0738e
The paper
Cats, E. A., van der Pol, W.-L., Piepers, S., Franssen, H., Jacobs, B. C., van den Berg-Vos, R. M., Kuks, J. B., van Doorn, P. A., van Engelen, B. G., Verschuuren, J. J., Wokke, J. H., Veldink, J. H., & van den Berg, L. H. (2010). Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology. https://doi.org/10.1212/wnl.0b013e3181f0738e

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.